Request Demo

Last update 08 May 2025

Recombinant human brain natriuretic peptide(Tibet Rhodiola Pharmaceutical Holding Co.)

Last update 08 May 2025

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Recombinant polypeptide, Biosimilar

Synonyms

Nesiritide Recombinant Biosimilar (Tibet Rhodiola Pharmaceutical Holding Co.), Recombinant Human Brain Natriuretic Peptide, 奈西立肽生物类似药（Tibet Rhodiola Pharmaceutical Holding Co.）

+ [2]

Target

NPRA

Action

agonists

Mechanism

NPRA agonists(Natriuretic peptide receptor 1 agonists)

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Heart Failure

Inactive Indication-

Originator Organization

Tibet Rhodiola Pharmaceutical Holding Co.

Active Organization

China Chengdu Rhodiola Biological Pharmaceutical Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhaseApproved

First Approval Date

China (11 Apr 2005),

Heart Failure

Regulation-

Structure/Sequence

Sequence Code 37334

The sequence is quoted from: *****

Clinical Trials associated with Recombinant human brain natriuretic peptide(Tibet Rhodiola Pharmaceutical Holding Co.)

NCT06463808

/ RecruitingNot ApplicableIIT

Effect of Recombinant Human Brain Natriuretic Peptide on Ventricular Remodeling and Cardiac Function in Patients With Acute Anterior Myocardial Infraction Undergoing Percutaneous Coronary Intervention

This study is designed to evaluate the efficacy and safety of Recombinant Human Brain Natriuretic Peptide (rhBNP) in improving ventricular remodeling and cardiac function after acute anterior myocardial infarction undergoing percutaneous coronary intervention. 100 patients with acute anterior myocardial infarction after primary Percutaneous Coronary Intervention (pPCI) are randomly assigned 1:1 to rhBNP group(n=50) and control group(n=50) with follow-up of 24 weeks. Both groups are treated with standard therapy of AAMI, with the rhBNP group intravenous dripping rhBNP after pPCI for 3 days and the control group treated with placebo at the same time. The primary endpoint is the change in N terminal pro-B-type natriuretic peptide（NT-proBNP ）and cardiac troponin T(cTnT) level.The secondary endpoint is the change in 24-week echocardiographic including left ventricle ejection fraction (LVEF) , left ventricular end-diastolic volume index (LVEDVI) and left ventricular end-systolic volume index (LVESVI), arrhythmia and cardiovascular events (death, cardiac arrest or cardiopulmonary resuscitation, hospitalization due to heart failure or angina pectoris).

Start Date03 May 2023

Sponsor / Collaborator

Jiangsu Provincial People's Hospital

ChiCTR2200065596

/ SuspendedPhase 4IIT

A prospective, multicenter, randomized, double-blind, placebo-controlled clinical study on the efficacy and safety of recombinant human brain natriuretic peptide in improving type 3 pulmonary hypertension

Start Date01 Nov 2022

Sponsor / Collaborator-

ChiCTR2300069664

/ RecruitingPhase 4IIT

Comparison of efficacy and safety of recombinant human brain natriuretic peptide in different courses on patients with acute heart failure

Start Date18 Feb 2022

Sponsor / Collaborator

Beijing Hospital of the Ministry of Health

100 Clinical Results associated with Recombinant human brain natriuretic peptide(Tibet Rhodiola Pharmaceutical Holding Co.)

100 Translational Medicine associated with Recombinant human brain natriuretic peptide(Tibet Rhodiola Pharmaceutical Holding Co.)

100 Patents (Medical) associated with Recombinant human brain natriuretic peptide(Tibet Rhodiola Pharmaceutical Holding Co.)

Literatures (Medical) associated with Recombinant human brain natriuretic peptide(Tibet Rhodiola Pharmaceutical Holding Co.)

25 Apr 2025·British Journal of Hospital Medicine

The Effects of Recombinant Human Brain Natriuretic Peptide in Combination With Sacubitril Valsartan Sodium on Cardiac Function, Inflammatory Markers, and Oxidative Stress Indicators in Elderly Patients With Acute Left Heart Failure: A Retrospective Study

Article

Author: Cheng, Zhi ; Gao, Yibing

Aims/Background Acute left ventricular failure (ALVF), a common cardiovascular emergency characterized by rapid occurring and progressing, poses a severe threat to the patient’s life. The purpose of this study is to investigate the impact of combining recombinant human brain natriuretic peptide (rhBNP) with sacubitril valsartan sodium on cardiac function, inflammatory markers, and oxidative stress indicators in elderly ALVF patients. Methods This retrospective study included 167 elderly ALVF patients between June 2022 and June 2024. Based on the treatment regimen, the patients were divided into three groups: a control group (n = 49, who received traditional treatment), an observation group (n = 61, who received replacement treatment with sacubitril and valsartan sodium), and a combination group (n = 57, who administered with a combination of rhBNP and sacubitril and valsartan sodium). Clinical data of patients were accessed from the electronic medical record system in the Second Affiliated Hospital of Nanjing Medical University, and the pre- and post-treatment cardiac function, inflammatory marker levels, oxidative stress indicators, and incidence of adverse reactions were compared among the three groups of patients. Results Following treatment, the left ventricular ejection fraction (LVEF) and superoxide dismutase (SOD) levels were significantly higher in the combination group compared to the observation and control groups. Furthermore, the combination group exhibited a substantial decrease in the left ventricular end-diastolic diameter (LVEDD), creatine kinase isoenzyme MB (CK-MB), alpha hydroxybutyrate dehydrogenase (α-HBDH), high-sensitivity C-reactive protein (hs-CRP), malondialdehyde (MDA) and tumor necrosis factor-alpha (TNF-α). Moreover, TNF-α, MDA and interleukin-6 (IL-6) levels were significantly lower in the observation group compared to the control group (p < 0.05). Additionally, no significant difference was observed in the incidence of adverse reactions between the two groups (p > 0.05). Conclusion Combining rhBNP with sacubitril and valsartan sodium can effectively improve the cardiac function among elderly ALVF patients, significantly reducing the levels of inflammatory factors and alleviating oxidative stress reactions. This approach provides superior efficacy and safety for managing elderly ALVF patients.

30 Mar 2022·International Heart JournalQ4 · MEDICINE

Effect of Recombinant Human Brain Natriuretic Peptide on Acute Carbon Monoxide Poisoning Complicated with Heart Failure with Reduced Ejection Fraction

Q4 · MEDICINE

Article

Author: Wang, Pu ; Xiao, Qingmian ; Wang, Weizhan ; Wang, Yan ; Xu, Wenpin ; Zhu, Baoyue

This paper aims to observe the effect of recombinant human brain natriuretic peptide (rhBNP) on treatment of acute carbon monoxide poisoning (ACMP) complicated with heart failure with reduced ejection fraction (HFREF).A total of 103 patients with ACMP complicated with HFREF admitted to our department from October 2016 to March 2020 were observed. Patients were divided into control group (50 cases) and experimental group (53 cases). The control group was given diuretic, vasodilator, and digitalis treatment, and the experimental group was supplemented with rhBNP treatment based on the control group. Patients' general information was collected. The levels of myocardial injury-associated indicators of patients were detected at and after admission.No significant differences were observed in the general data of patients compared with control group. The acute physiology and chronic health enquiry II score of patients was positively correlated with left ventricular ejection fraction (LVEF). At admission, the levels of myocardial injury indicators, N-terminal B-type brain natriuretic peptide, and cardiac ultrasound indexes had no significant difference between the control group and experimental group. However, after admission, the LVEF and stroke output levels were elevated, while the other indicators were all decreased compared with the control group.The rhBNP exerts a protective effect on ACMP-induced cardiomyocyte injury to improve cardiac function, shorten the length of hospital stay, and reduce the incidence and mortality of delayed encephalopathy after carbon monoxide poisoning.

29 Jan 2022·International Heart Journal

Effects of Recombinant Human Brain Natriuretic Peptide in Patients with Acute Pulmonary Embolism Complicated with Right Ventricular Dysfunction Who Underwent Catheter-Directed Therapy

Article

Author: Xu, Hui ; Fu, Mingming ; Wang, Jianjie ; Meng, Xiangdong

Acute pulmonary embolism (PE) remains a significant cause of cardiovascular morbidity and mortality worldwide. Brain natriuretic peptide (BNP) combined with catheter-directed therapy (CDT) may improve right ventricular (RV) dysfunction and stabilize hemodynamics in acute PE.We retrospectively studied 159 patients with confirmed acute PE who were treated with CDT and admitted to the intensive care unit of our department between September 2016 and May 2020. The patients were divided into the control group and the rhBNP group based on whether to receive recombinant human BNP treatment (rhBNP) or not. The basic characteristics of the patients between the control group and the rhBNP group was systematically compared during admission and follow-up. Risk factors for all-cause mortality within 30 days were determined using multivariate logistic regression analysis.Respiratory rate was found to be significantly lower in the rhBNP group than in the control group. Patients in the rhBNP group had significantly lower levels of white blood cell, C-reactive protein (CRP), D-dimers, troponin I, creatinine, and N-terminal (NT) -proBNP compared with those in the control group. Levels of tricuspid annular plane systolic excursion were significantly higher in the rhBNP group than in the control group. The percentage of patients with rehospitalization readmission due to PE differed significantly between the control group and the rhBNP group. On the basis of the multivariate regression analysis, CRP, creatinine, troponin I, and NT-proBNP were independent factors of all-cause mortality in 30 days.rhBNP is effective in the treatment of patients with RV dysfunction caused by acute PE who underwent CDT, which may be an alternative treatment option for improving clinical prognosis.

100 Deals associated with Recombinant human brain natriuretic peptide(Tibet Rhodiola Pharmaceutical Holding Co.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	C01DX19	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Heart Failure	China	China Chengdu Rhodiola Biological Pharmaceutical Co., Ltd.	11 Apr 2005

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis